Outcomes research in dialysis

Seminars in Nephrology

Volumn 23, Issue 3, 2003, Pages 295-305

  Dhingra, Hemant ^a   Laski, Melvin E ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

ANEMIA; ARTERIOVENOUS FISTULA; CHRONIC KIDNEY FAILURE; CREATININE CLEARANCE; DEATH; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOCRIT; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPOALBUMINEMIA; INTRAVASCULAR CATHETER; MEDICAL LITERATURE; MORTALITY; NEPHROLOGY; NUTRITIONAL SUPPORT; OUTCOMES RESEARCH; PATIENT CARE; PATIENT REFERRAL; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; VASCULAR ACCESS;

EID: 0038495662     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0270-9295(03)00065-2     Document Type: Article

References (66)

1. U.S. Renal Data System 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States: Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001
2. U.S. Renal Data System 2000 Annual Data Report: Atlas of End-Stage Renal Disease in the United States: Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2000
3. McClellan WM, Anson CA, Tuttle E: Functional status and quality of life: Predictors of early mortality among patients entering treatment for end stage renal disease. J Clin Epidemiol 44:83-89, 1991
4. DeOreo PB: Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis 30:204-212, 1997
5. Hull A, Parker T: Proceedings from the Morbidity, Mortality, and Prescription of Dialysis Symposium, Dallas, Texas, September 15 to 17, 1989. Am J Kidney Dis 15:375-383, 1990
6. Health Care Financing Administration: 1999 Annual Report, End-Stage Renal Disease Clinical Performance Measures Project. Baltimore, MD, Department of Health and Human Services, HCFA, Office of Clinical Standards and Quality, 1999
7. Association for the Advancement of Medical Instrumentation: AAMI Standards and Recommended Practices. vol 3, Dialysis: Arlington, VA, AAMI, 1996
8. Eknoyan G, Levin N: Clinical Practice Guidelines: Final Guideline summaries from the Work Groups of the National Kidney Foundation-Dialysis Outcomes Quality Initiative: New York, NY, National Kidney Foundation, 1997
9. NKF-K/DOQI: Clinical Practice Guidelines: Update 2000. Am J Kidney Dis 37:S7-S238, 2001 (suppl 1)
10. K/DOQI, National Kidney Foundation: Clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 35:S1-S140, 2000 (suppl 2)
11. Iglehart JK: The end stage renal disease program. N Engl J Med 328:366-371, 1993
12. Health Care Financing Administration: 2000 Annual Report, ESRD Clinical Performance Measures Project: Baltimore, Health Care Financing Administration, 2000
13. Lohr KN (ed): Medicare: A strategy for quality assurance: Washington, DC, National Academy Press, 1990
14. Fishbane S, Goldman R: Quality outcomes and obstacles to their achievements in end-stage renal disease. Semin Dial 15:30-34, 2002
15. Held PJ, Port FK, Wolfe RA, et al: The dose of hemodialysis and patient mortality. Kidney Int 50:550-556, 1996
16. Sehgal AR, Dor A, Tsai AC: The morbidity and cost implications of inadequate hemodialysis. Am J Kidney Dis 37:1223-1231, 2001
17. Wolfe RA, Ashby VB, Milford EL, et al: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341:1725-1730, 1999
18. Rocco MV, Soucie JM, Reboussin DM, et al: Risk factors for hospital utilization in chronic dialysis patients. J Am Soc Nephrol 7:889-896, 1996
19. Feldman HI, Kobrin S, Wasserstein A: Hemodialysis vascular access morbidity. J Am Soc Nephrol 7:523-535, 1996
20. Obrador GT, Roberts T, St Peter WL, et al: Trends in anemia at initiation of dialysis in the United States. Kidney Int 60:1875-1884, 2001
21. Kleinman KS, Schweitzer SU, Perdue ST, et al: The use of recombinant human erythropoietin in the correction of anemia in predialysis and its effect on renal function: A double-blind, placebo-controlled trial. Am J Kidney Dis 14:486-495, 1989
22. Revicki DA, Brown RE, Feeny DH, et al: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25:548-554, 1995
23. Wolcott DL, Marsh JT, La Rue A, et al: Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 14:478-485, 1989
24. Delano BG: Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 14:14-18, 1989
25. Rocco MV, Yan G, Gassman J, et al: Comparison of causes of death notification classification systems. The National Institutes of Health-Funded Hemodialysis. Health Care Financing Administration. Am J Kidney Dis 39:146-153, 2002
26. Foley RN, Parfrey PS, Harnett JD, et al: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47:186-192, 1995
27. Levin A, Singer J, Thompson CR, et al: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27:347-354, 1996
28. Levin A, Thompson CR, Ethier J, et al: Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 34:125-134, 1999
29. Luft FC: Erythropoietin and arterial hypertension. Clin Nephrol 53:S61-S64, 2000
30. Vaziri ND: Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 33:821-828, 1999
31. Nowicki M: Erythropoietin and hypertension. J Hum Hypertens 9:81-88, 1995
32. Kokot F, Wiecek A: Arterial hypertension in uraemic patients treated with erythropoietin. Nephron 71:127-132, 1995
33. Garcia DL, Anderson S, Rennke HG, et al: Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci U S A 85:6142-6146, 1988
34. Roth D, Smith RD, Schulman G, et al: Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24:777-784, 1994
35. Lim VS, Fangman J, Flanigan MJ, et al: Effect of recombinant human erythropoietin on renal function in humans. Kidney Int 37:131-136, 1990
36. Abraham PA, Opsahl JA, Rachael KM, et al: Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol 10:128-136, 1990
37. Frenken LA, Verberckmoes R, Michielsen P, et al: Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients. Nephrol Dial Transplant 4:782-7867, 1989
38. Jungers P, Choukroun G, Oualiim Z, et al: Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 16:307-312, 2001
39. Kuriyama S, Tomonari H, Yoshida H, et al: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77:176-185, 1997
40. Feldman HI, Kobrin S, Wasserstein A: Hemodialysis vascular access morbidity. J Am Soc Nephrol 7:523-535, 1996
41. Feldman HI, Held PJ, Hutchinson JT, et al: Hemodialysis vascular access morbidity in the United States. Kidney Int 43:1091-1096, 1993
42. NKF-K/DOQI: Clinical Practice Guidelines for Vascular Access: Update 2000. Am J Kidney Dis 37:S137-S181, 2001 (suppl 1)
43. Pisoni RL, Young EW, Dykstra DM, et al: Vascular access use in Europe and the United States: Results from the DOPPS. Kidney Int 61:305-316, 2002
44. Stehman-Breen CO, Sherrard DJ, Gillen D, et al: Determinants of type and timing of initial permanent hemodialysis vascular access. Kidney Int 57:639-645, 2000
45. Rodriguez JA, Armadans L, Ferrer E, et al: The function of permanent vascular access. Nephrol Dial Transplant 15:402-408, 2000
46. Pisoni RL, Young EW, Dykstra DM, et al: Vascular access use in Europe and the United States: Results from the DOPPS. Kidney Int 61:305-316, 2002
47. Khosla N, Ahya SN: Improving dialysis access management. Semin Nephrol 22:507-514, 2002
48. Foley R, Levey A, Sarnak M: Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 32:S112-S119, 1998 (suppl 3)
49. Churchill D, Taylor D, Cook R, et al: Canadian hemodialysis morbidity study group. Am J Kidney Dis 19:214-234, 1992
50. Rettig RA, Sadler JH, Meyer KB, et al: Assessing health and quality-of-life outcomes in dialysis: A report to an Institute of Medicine Workshop. Am J Kidney Dis 30:140-156, 1997
51. Gombos EA, Lee TH, Harton MR, et al: One year's experience with an intermittent dialysis program. Ann Intern Med 61:462-469, 1964
52. Gill TM, Feinstein AR: A critical appraisal of the quality-of-life measurements. JAMA 272:619-626, 1994
53. Meyer KB, Espindle DM, DeGiacomo JM, et al: Monitoring dialysis patients' health status. Am J Kidney Dis 24:267-279, 1994
54. Edgell ET, Coons SJ, Carter WB, et al: A review of health-related quality-of-life measures used in end-stage renal disease. Clin Ther 18:887-938, 1996
55. Diaz-Buxo JA, Lowrie EG, Lew NL, et al: Quality-of-life evaluation using short form 36: Comparison in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 35:293-300, 2000
56. Simmons RG, Anderson CR, Bress LK, et al: Quality of life and rehabilitation differences among four ESRD therapy groups. Scand J Urol Nephrol 131:S7-S22, 1990
57. Bindman AB, Keane D, Lurie N: Measuring health changes among severely ill patients: The floor phenomenon. Med Care 28:1142-1152, 1990
58. Alonso J, Prieto L, Ferrer M, et al: Testing the measurement properties of the Spanish version of the SF-36 Health Survey among male patients with chronic obstructive pulmonary disease. Quality of Life in COPD Study Group: J Clin Epidemiol 51:1087-1094, 1998
59. O'Mahony PG, Rodgers H, Thomson RG, et al: Is the SF-36 suitable for assessing health status of older stroke patients? Age Ageing 27:19-22, 1998
60. Powe NR, Klag MJ, Saddler JH, et al: Choices for healthy outcomes in caring for end-stage renal disease. Semin Dial 9:9-11, 1996
61. Patrick DL, Erickson P: Health Status and Health Policy: Allocating Resources to Health Care. New York, NY, Oxford, 1993, p 419
62. Blagg CR: Objective quantification of rehabilitation in dialysis and transplantation. In Friedman EA, ed: Strategy in Renal Failure. New York, NY, Wiley, 1978, pp 415-433
63. Cameron JI, Whiteside C, Katz J, et al: Differences in quality of life access across renal replacement therapies: A meta-analytic comparison. Am J Kidney Dis 35:629-637, 2000
64. Levey AS, Beto JA, Coronado BE, et al: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Am J Kidney Dis 32:853-906, 1998
65. Port F: Morbidity and mortality in dialysis patients. Kidney Int 46:1728-1737, 1999
66. Leavey SF, Strawderman RL, Jones CA, et al: Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis 31:997-1006, 1998